HC Wainwright Forecasts Strong Price Appreciation for ArriVent BioPharma (NASDAQ:AVBP) Stock

ArriVent BioPharma (NASDAQ:AVBP) had its price objective hoisted by analysts at HC Wainwright from $39.00 to $40.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 107.90% from the stock’s previous close. HC Wainwright also issued estimates for ArriVent BioPharma’s FY2026 earnings at ($2.99) EPS.

Several other equities analysts have also issued reports on AVBP. Guggenheim started coverage on ArriVent BioPharma in a research note on Monday, March 10th. They issued a “buy” rating and a $45.00 target price on the stock. B. Riley started coverage on ArriVent BioPharma in a report on Thursday, March 20th. They issued a “buy” rating and a $37.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ArriVent BioPharma currently has an average rating of “Buy” and an average price target of $39.17.

ArriVent BioPharma Price Performance

AVBP opened at $19.24 on Wednesday. The business’s 50-day moving average is $19.31 and its two-hundred day moving average is $24.59. ArriVent BioPharma has a 1 year low of $15.47 and a 1 year high of $36.37. The firm has a market capitalization of $658.26 million, a PE ratio of -5.10 and a beta of 1.47.

ArriVent BioPharma (NASDAQ:AVBP) last posted its earnings results on Monday, May 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($1.24). As a group, sell-side analysts expect that ArriVent BioPharma will post -2.74 EPS for the current year.

Institutional Investors Weigh In On ArriVent BioPharma

Institutional investors have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC boosted its position in ArriVent BioPharma by 21.7% in the fourth quarter. Suvretta Capital Management LLC now owns 2,246,000 shares of the company’s stock valued at $59,833,000 after buying an additional 400,838 shares during the last quarter. Octagon Capital Advisors LP boosted its position in ArriVent BioPharma by 4.2% in the fourth quarter. Octagon Capital Advisors LP now owns 2,059,387 shares of the company’s stock valued at $54,862,000 after buying an additional 83,000 shares during the last quarter. Infinitum Asset Management LLC purchased a new stake in ArriVent BioPharma in the fourth quarter valued at approximately $43,794,000. Novo Holdings A S boosted its position in ArriVent BioPharma by 1.0% in the fourth quarter. Novo Holdings A S now owns 1,520,627 shares of the company’s stock valued at $40,510,000 after buying an additional 15,312 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in ArriVent BioPharma by 6.1% in the first quarter. Vanguard Group Inc. now owns 1,503,358 shares of the company’s stock valued at $27,797,000 after buying an additional 86,067 shares during the last quarter. Institutional investors and hedge funds own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.